Clinical trials: Propionibacterium
Acne Vulgaris, Acne
Safety and Efficacy of MBI 226 1.25% and 2.5% Topical Acne Solutions in the Treatment of Acne
This is a Phase II, randomized, vehicle-controlled, double-blind, multi center study to evaluate the efficacy and safety of topically applied MBI 226 1.25% and 2.5% Acne Solutions as anti-acne preparations in human subjects with…
- Conditions
- Acne Vulgaris, Acne, Propionibacterium Acnes
- Trial name
- NCT00211497
- Testing
- MBI 226 Acne Solutions
- Volunteers
- 255 people
- Sponsor
- BioWest Therapeutics Inc
Acne Vulgaris, Acne
Safety and Efficacy of MBI 226 2.5% and 5.0% Topical Acne Solutions in the Treatment of Acne
This study investigates the safety and efficacy of MBI 226 2.5% and 5.0% Acne Solutions, applied topically for six weeks, in the treatment of acne.
- Conditions
- Acne Vulgaris, Acne, Propionibacterium Acnes
- Trial name
- NCT00211523
- Testing
- MBI 226 Acne Solutions
- Volunteers
- 75 people
- Sponsor
- BioWest Therapeutics Inc